etoposide has been researched along with Blood Diseases in 139 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (15.11) | 18.7374 |
| 1990's | 60 (43.17) | 18.2507 |
| 2000's | 36 (25.90) | 29.6817 |
| 2010's | 21 (15.11) | 24.3611 |
| 2020's | 1 (0.72) | 2.80 |
| Authors | Studies |
|---|---|
| Aurer, I; Dreta, B; Dujmovic, D; Gacina, P; Galusic, D; Holik, H; Jaksic, O; Kinda, SB; Mitrovic, Z; Pejsa, V; Perisa, V; Prka, Z | 1 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Barnoud, D; Béné, J; Bruno, B; Odou, P; Simon, N; Vasseur, M | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Berdel, WE; Demant, A; Evers, G; Kessler, T; Köhler, G; Krug, U; Kuhlmann, M; Mesters, R; Mikesch, JH; Mohr, M; Müller-Tidow, C; Pohlen, M; Schliemann, C; Schmidt, E; Thoennissen, GB; Thoennissen, NH; Wessling, J | 1 |
| Abate, ME; Balladelli, A; Cesari, M; Fagioli, F; Ferrari, S; Luksch, R; Marchesi, E; Paioli, A; Palmerini, E; Pratelli, L; Tamburini, A | 1 |
| Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC | 1 |
| Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J | 1 |
| Kobayashi, S; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, I; Okamoto, K; Takeda, K; Takeda, M | 1 |
| Fujii, Y; Fukui, I; Masuda, H; Sakura, M; Tanaka, H; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Koo, DH; Lee, HS; Lee, SS; Lee, YG; Lim, SY; Nam, H; Oh, S; Song, JU | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Ross, HJ; Seung, SK | 1 |
| Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A | 1 |
| Choi, MK; Jun, HJ; Kim, K; Kim, KH; Kim, SJ; Kim, WS; Ko, YH; Lee, SY; Lim, DH | 1 |
| Grodman, H; Kretschmar, C; Wolfe, L | 1 |
| Commander, LA; Insogna, IG; Rheingold, SR; Seif, AE | 1 |
| Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, D; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL | 1 |
| Kanamori, M; Kumabe, T; Saito, R; Sonoda, Y; Tominaga, T; Yamashita, Y | 1 |
| Bozhenko, VK; Datsenko, PV; Pan'shin, GA; Podol'skiĭ, PN; Sotnikov, VM | 1 |
| Hayama, M; Nakamine, H; Nakamura, S; Niitsu, N; Okamoto, M; Tamaru, J; Yoshino, T | 1 |
| Batsuren, D; Jho, EH; Kang, JH; Kang, K; Kim, M; Nho, CW; Oh, SH; Park, KH; Tunsag, J; Yun, JH | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Advani, R; Bartlett, NL; Cheson, BD; Connors, JM; Evens, AM; Fisher, RI; Gascoyne, RD; Gordon, LI; Gospodarowicz, M; Hong, F; Hoppe, RT; Horning, SJ; Kahl, BS; Miller, TP; Stiff, PJ; Wagner, H | 1 |
| Ahn, JS; Chae, YS; Jung, SH; Kim, HJ; Kim, YK; Kwak, JY; Lee, JJ; Lee, SR; Sohn, SK; Yang, DH; Yhim, HY | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Berdel, WE; Dölken, G; Kienast, J; Klinke, F; Macha, H; Mohr, M; Oelmann, E; Schmidt, EW; Serve, H; Thomas, M; Zühlsdorf, M | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K | 1 |
| Finckenstein, FG; Graf, N; Gruhn, B; Hasan, C; Hero, B; Klingebiel, T; Koscielniak, E; Kremens, B; Laws, HJ; Niemeyer, C; Schulz, A; Selle, B; Wawer, A; Zintl, F | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Bosi, A; Carpaneto, A; Carrai, V; Longo, G; Rigacci, L; Rossi Ferrini, P | 1 |
| Baujan, MA; Bourekas, EC; Chakeres, DW; Christoforidis, GA; Newton, HB; Slivka, MA; Slone, W; Volpi, C | 1 |
| Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A | 1 |
| Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J | 1 |
| Alamanis, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Giannopoulos, A; Gika, D; Kiamouris, C; Koutsilieris, M; Zervas, A | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M | 1 |
| Calabrese, L; Cavalli, F; Cocorocchio, E; Ghielmini, M; Martinelli, G; Mazzetta, C; Pastano, R; Peccatori, F; Pruneri, G; Saletti, PC; Zucca, E | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T | 1 |
| Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Bentz, M; Dührsen, U; Einsele, H; Lengfelder, E; Loeffler, M; Mergenthaler, HG; Mesters, R; Pflüger, KH; Pfreundschuh, M; Rübe, C; Schmitz, N; Trümper, L; Vrieling, T; Zeynalova, S; Zwick, C | 1 |
| Bentz, M; Graeven, U; Hasenclever, D; Hoffmann, M; Hohloch, K; Liersch, R; Loeffler, M; Metzner, B; Mohren, M; Pfreundschuh, M; Schmits, R; Trümper, L; Wruck, U; Ziepert, M; Zwick, C | 1 |
| Aversa, S; Brunsvig, P; Lange, A; Leyvraz, S; Martinelli, G; Montes, A; Pampallona, S; Perey, L; Peters, S; Ploner, F; Rosti, G; Yilmaz, U | 1 |
| Gracia, JM; Jimenez, A | 1 |
| Albain, KS; Bitran, JD; Blough, RR; DeMeester, TR; Golomb, HM; Hoffman, PC; Noble, S; Skosey, C | 1 |
| Aisner, J; Van Echo, DA; Whitacre, M; Wiernik, PH | 1 |
| Eguchi, K; Fukuda, M; Kasai, T; Kurata, T; Ohe, Y; Oshita, F; Saijo, N; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Bunn, PA; Kelly, KL | 1 |
| Bonilla, MA; Cheung, NK; Eddy, J; Gerald, WL; Heller, G; Kushner, BH; LaQuaglia, MP; Lindsley, K; Rosenfield, N; Yeh, S | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE | 1 |
| Bezwoda, WR; Dansey, RD; Seymour, L | 1 |
| Cooper, MA; Einhorn, LH | 1 |
| Ansari, R; Einhorn, LH; Faylona, EA; Gonin, R; Loehrer, PJ; Sandler, AB | 1 |
| Arnaud, A; Blanchon, F; Bonnaud, F; Castelnau, O; Guérin, JC; Kleisbauer, JP; Pérol, M; Taytard, A; Vergnenegre, A | 1 |
| Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C | 1 |
| Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A | 1 |
| Bajetta, E; Bochicchio, AM; Bozzetti, F; Comella, P; de Braud, F; Di Bartolomeo, M; Fagnani, D; Farina, G; Ferroni, C; Franchi, R | 1 |
| Boutard, P; Brunat-Mentigny, M; Deville, A; Dusol, F; Gentet, JC; Legall, E; Mechinaud, F; Pein, F; Tournade, MF; Zucker, JM | 1 |
| Ando, Y; Minami, H; Nomura, F; Saito, H; Saka, H; Sakai, S; Senda, K; Shimokata, K | 1 |
| Alberto, P; Beris, P; Cabrol, C; Jotterand Bellomo, M; Mermillod, B; Zulian, GB | 1 |
| Falk, M; Fridrik, MA; Haidinger, R; Hausmaninger, H; Klocker, J; Linkesch, W; Neubauer, M; Pont, J; Radaszkiewicz, T; Raudaschl, G; Schiller, L; Seewann, HL; Sill, H; Stöger, M | 1 |
| Clark, PI; Joel, SP; Shah, R; Slevin, ML | 1 |
| Mempel, K; Pfetsch, M; Reiter, A; Riehm, H; Schrappe, M; Schwab, G; Welte, K | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gonzalves, L; Lokich, J; Moore, C; Zipoli, T | 1 |
| Friedman, HS; Heideman, RL; Murry, DJ; Petros, WP; Rodman, JH; Tonda, ME | 1 |
| Chen, S; Lee, BC; Miller, AA; Molthrop, DC; Robert, F; Wheeler, RH | 1 |
| Crowley, JJ; Figlin, RA; Goodwin, JW; Jacobs, EL; Livingston, RB; Muirhead, M; Rinehart, JJ | 1 |
| Bolzicco, G; Crinó, L; De Marinis, F; Emiliani, E; Figoli, F; Gentile, A; Marangolo, M; Maranzano, E; Masiero, P; Meacci, L; Morandi, MG; Ricardi, U; Rosti, G; Scagliotti, GV; Tonato, M | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Di Lollo, S; Ferrini, PR; Fusco, II; Innocenti, F; Longo, G; Rigacci, L; Stefanacci, S | 1 |
| Ang, PT; Au, E; Koo, WH; Tan, EH | 1 |
| Anderson, E; Anderson, T; Cameron, DA; Chetty, U; Craig, J; Dixon, M; Gabra, H; Hawkins, A; Jack, W; Kunkler, I; Lee, L; Leonard, R; Leonard, RC; MacKay, J; Matheson, L; Miller, W; Parker, AC | 1 |
| Barbhaiya, RH; Igwemezie, LN; Kaul, S; Srinivas, NR | 1 |
| Alberts, DS; Brooks, DJ | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Benedetti Panici, P; Caracussi, U; Foddai, ML; Leone, G; Mancuso, S; Maneschi, F; Menichella, G; Pierelli, L; Salerno, MG; Scambia, G; Serafini, R; Vittori, M | 1 |
| Golding, PF; Hamilton, CR; Kerr, J; Mead, GM; Milne, AE; O'Callaghan, A; Simmonds, PD; Smartt, P; Sweetenham, JW; Whitehouse, JM | 1 |
| Byhardt, RW; Curran, W; Ettinger, D; Evans, RF; Fossella, FV; Komaki, R; Lee, JS; Rubin, P; Scott, C | 1 |
| Ando, M; Eguchi, K; Hojo, N; Kakinuma, R; Kasai, T; Kodama, T; Kubota, K; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Beijnen, JH; Dubbelman, AC; Groot, Y; Herben, VM; Mandjes, IA; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM | 1 |
| Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE | 1 |
| Hara, N; Hirose, N; Inutsuka, S; Kanegae, H; Kawarada, Y; Kurita, Y; Miyazaki, M; Miyazaki, N; Nakanishi, Y; Ninomiya, K; Ogata, K; Ohgushi, O; Yamazaki, H | 1 |
| Dardoufas, C; Dimitroulis, J; Jordanoglou, J; Katsilambros, N; Latsi, P; Polyzos, A; Rasidakis, A; Stamatiadis, D; Veslemes, M | 1 |
| Iitsuka, Y; Matsui, H; Seki, K; Sekiya, S | 1 |
| Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Bergman, B; Helsing, M; Hero, U; Thaning, L | 1 |
| Alberto, P; Bacchi, M; Borner, MM; Castiglione, M; Herrmann, R; Honegger, HP; Lange, J; Morant, R; Obrist, R; Roth, AD | 1 |
| Buckner, JC; Groover, RV; Kimmel, DW; Neglia, J; O'Fallon, JR; Peethambaram, PP; Raffel, C; Schomberg, PJ; Shaw, EG; Smithson, WA | 1 |
| Astoul, P; Boutin, C; Kasseyet, S | 1 |
| Baker, D; Coccia, P; Cramer, LD; Dunkel, IJ; Finlay, JL; Garvin, J; Goldman, S; Kaplan, AM; Klemperer, M; Kramer, E; Packer, RJ; Papadakis, V; Papadopoulos, E; Strandjord, S; Willoughby, M | 1 |
| Bonomi, PD; Kucuk, O; Pandya, KJ; Shevrin, DH | 1 |
| Chamberlain, MC; Glantz, MJ; Greenberg, HS; Wang, S | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Nikolic, N; Shibamoto, Y | 1 |
| Ahn, YC; Han, J; Huh, SJ; Kim, DY; Kim, HJ; Kim, J; Kim, KM; Kwon, J; Lee, JE; Lee, KS; Lim, DH; Noh, YJ; Park, K; Shim, YM | 1 |
| De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G | 1 |
| Mahmoudi, M; Meyer, T; Nelstrop, AE; Rustin, GJ | 1 |
| Carde, P; Cavalli, F; Diehl, V; Franklin, J | 1 |
| Abu-Ghosh, AM; Cairo, MS; Davenport, V; Goldman, SC; Krailo, MD; Laver, JH; Morris, E; Reaman, GH; Slack, RS | 1 |
| Amato, RJ; Daliani, D; Do, KA; Finn, L; Fizazi, K; Kim, J; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Papandreou, CN; Prow, DM; Tu, SM; Wang, X | 1 |
| Hansen, HH; Lau, ME; Nissen, NI; Pedersen, H | 1 |
| Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Lombardi, F; Magni, M; Pileri, A; Siena, S; Tarella, C | 1 |
| Griffin, JP; Miller, AA; Niell, HB; Stewart, CF; Tolley, EA | 1 |
| Finlay, JL; McElwain, M; Packer, RJ; Pons, MA; Puccetti, D; Walker, RW | 1 |
| Abate, G; Comella, P; Daponte, A; Di Finizio, G; Zarrilli, D | 1 |
| Altman, SJ; Blumenstein, BA; Bouroncle, BA; Crawford, ED; Ford, CD; Natale, RB; Samson, MK; Shah, NT; Stephens, RL; Wozniak, AJ | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Johnson, DH; McMaster, ML; Wolff, SN | 1 |
| Gumbrell, LA; Harland, SJ; Horwich, A | 1 |
| Kredentser, DC | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Pedersen, AG; Sörenson, S | 1 |
| Haim, N; Robinson, E | 1 |
| Albertini, M; Saphner, T; Tormey, DC | 1 |
| Fukuoka, M; Kawahara, M; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Tachikawa, A; Takada, M; Takifuji, N | 1 |
| Einhorn, LH; McClean, J; Pennington, K | 1 |
| Einhorn, LH; Miller, JC | 1 |
| Chan, KW; Fryer, CJ; Steinbok, P | 1 |
| Carey, PJ; Jackson, GH; Lennard, AL; Proctor, SJ | 1 |
| Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA | 1 |
| Becquart, D; Dalesio, O; Dumont, JP; Klastersky, J; Longeval, E; Michel, J; Rocmans, P; Sculier, JP; Vandermoten, G | 1 |
| Birch, R; Greco, FA; Sarma, P; Wolff, SN | 1 |
| Bonduelle, Y; Klastersky, J; Libert, P; Mairesse, M; Michel, J; Michiels, T; Ravez, P; Rocmans, P; Sculier, JP; Vandermoten, G | 1 |
| Budd, GT; Coltman, CA; Crowley, JP; Grever, MR; Harker, G; Livingston, RB; Mira, JG; Rivkin, SE; Schulman, S; Vogel, S | 1 |
| Aisner, J; Poplin, E; Thompson, B; Whitacre, M | 1 |
| Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Sørensson, S; Vindeløv, LL | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Dalton, RJ; Gerstner, JB; Letendre, L; Levitt, R; Mailliard, JA; Pierre, RV; Therneau, TM | 1 |
| Birch, R; Einhorn, LH; Greco, FA; Troner, M; Walther, PJ; Williams, SD | 1 |
| Bartolucci, AA; Gockerman, JP; Nelson, MO; Silberman, H; Stein, R; Velez-Garcia, E | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS | 1 |
| Atkins, JN; Capizzi, RL; Caponera, ME; Craig, JB; Jackson, DV; Muss, HB; Powell, BL; Richards, F; White, DR; Zekan, PJ | 1 |
| De Lena, M; Lorusso, V; Romito, S | 1 |
| Gordon, LI; Hauck, WW; Variakojis, D; Winter, JN | 1 |
| Fahey, JL; Farbstein, MJ; Forman, SJ; Gill, P; Lazar, G; Levine, AM; Nademanee, A; Neely, S; O'Donnell, MR; Territo, M | 1 |
| Abromowitch, M; Bowman, WP; Ochs, J; Rivera, G | 1 |
8 review(s) available for etoposide and Blood Diseases
| Article | Year |
|---|---|
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning | 2014 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
Adult medulloblastoma: multiagent chemotherapy.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid Shunts; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Hearing Loss, Sensorineural; Hematologic Diseases; Humans; Infratentorial Neoplasms; Life Tables; Lomustine; Male; Medulloblastoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Vincristine | 2001 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hodgkin Disease; Humans; Infertility; Mechlorethamine; Prednisolone; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Safety; Treatment Outcome; Vinblastine; Vincristine | 2000 |
77 trial(s) available for etoposide and Blood Diseases
| Article | Year |
|---|---|
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Ifosfamide; Male; Melphalan; Mesna; Neoplasm Staging; Prognosis; Prospective Studies; Sarcoma, Ewing; Sex Factors; Survival Rate; Vincristine; Young Adult | 2014 |
A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Gamma Rays; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Radiation Dosage; Small Cell Lung Carcinoma; Thorax | 2014 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Ifosfamide; Infant; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Sarcoma, Ewing; Vincristine | 2008 |
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Nervous System Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2011 |
Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cyclophosphamide; Doxorubicin; Epidemiologic Methods; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Proteins; NM23 Nucleoside Diphosphate Kinases; Prednisolone; Prognosis; Treatment Outcome; Vincristine; Young Adult | 2011 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Lung Diseases; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2013 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Germany; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Prednisolone; Prednisone; Recombinant Proteins; Survival Rate; Vincristine | 2003 |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus; Disease-Free Survival; Estramustine; Etoposide; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Orchiectomy; Peptides, Cyclic; Prostatic Neoplasms; Somatostatin; Survival Analysis; Treatment Outcome; Triptorelin Pamoate | 2004 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; Vincristine | 2008 |
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Erythrocyte Transfusion; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Platelet Transfusion; Prednisolone; Remission Induction; Vincristine | 2008 |
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Incidence; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Prognosis; Research Design; Survival Analysis; Treatment Outcome | 2008 |
Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Peplomycin; Pilot Projects; Survival Rate; Thyroid Neoplasms; Thyroidectomy | 1995 |
Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome | 1995 |
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 1995 |
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Length of Stay; Male; Middle Aged; Neoplasms; Transplantation, Autologous; Treatment Outcome | 1994 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Heart Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Mitoxantrone; Neutropenia; Pilot Projects; Platelet Count; Remission Induction; Survival Rate; Vincristine | 1995 |
Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors.
Topics: Administration, Oral; Bone Marrow Transplantation; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Germinoma; Hematologic Diseases; Humans; Male; Mediastinal Neoplasms; Ovarian Neoplasms; Remission Induction; Salvage Therapy | 1995 |
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Topics: Administration, Oral; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis | 1995 |
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Neoplasms; Transplantation, Autologous; Treatment Outcome | 1994 |
Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Prognosis; Stomach Neoplasms | 1994 |
Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infant; Kidney Neoplasms; Male; Neoplasm Staging; Remission Induction; Thrombocytopenia; Wilms Tumor | 1994 |
Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
Topics: Adult; Aged; Catheterization, Central Venous; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1993 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Feasibility Studies; Female; Folic Acid; Hematologic Diseases; Humans; Ifosfamide; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Remission Induction; Risk Factors; Survival Rate; Vincristine | 1996 |
Predicting etoposide toxicity: relationship to organ function and protein binding.
Topics: Adult; Aged; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Creatinine; Etoposide; Female; Half-Life; Hematologic Diseases; Humans; Kidney Function Tests; Leukocyte Count; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Protein Binding; Regression Analysis | 1996 |
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Fever; Filgrastim; Gastrointestinal Diseases; Germany; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Infant; Infection Control; Life Tables; Male; Mercaptopurine; Methotrexate; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prospective Studies; Recombinant Proteins; Risk; Survival Analysis; Thioguanine; Vincristine; Vindesine | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Lung Neoplasms; Male; Middle Aged | 1996 |
Carboplatin pharmacokinetics in young children with brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Etoposide; Glomerular Filtration Rate; Hematologic Diseases; Humans; Prospective Studies; Reproducibility of Results; Statistics, Nonparametric | 1996 |
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Creatinine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Statistics, Nonparametric; Stomatitis | 1996 |
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Etoposide; Female; Hematologic Diseases; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1996 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Recombinant Proteins; Survival Rate | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Levoleucovorin; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Rate | 1996 |
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chi-Square Distribution; Confidence Intervals; Diarrhea; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Liver Neoplasms; Lung Neoplasms; Melphalan; Middle Aged; Neoplasm Staging; Survival Rate; Thiotepa; Treatment Outcome | 1996 |
A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Etoposide; Female; Granulocytes; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Organophosphorus Compounds; Regression Analysis | 1996 |
A phase I study of etoposide phosphate plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel | 1996 |
Clinical studies with etoposide phosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Remission Induction | 1996 |
High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Length of Stay; Melphalan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recombinant Proteins; Survival Rate | 1997 |
PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fertility; Follow-Up Studies; Hematologic Diseases; Hodgkin Disease; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Treatment Outcome; Vincristine | 1997 |
Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Vinblastine | 1997 |
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 1998 |
Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Hematologic Diseases; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Nausea; Remission Induction; Survival Analysis | 1998 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cognition; Disease Progression; Emotions; Etoposide; Female; Hematologic Diseases; Humans; Interpersonal Relations; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome | 1998 |
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Male; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 1998 |
Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Germinoma; Hematologic Diseases; Humans; Male; Prospective Studies; Radiotherapy Dosage; Remission Induction; Vomiting | 1999 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality Therapy; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Immunotherapy; Leucovorin; Male; Mesothelioma; Middle Aged; Mitomycin; Pleural Neoplasms; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 1999 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Diarrhea; Disease Progression; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Survival Rate | 2000 |
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Ifosfamide; Infant; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome; Wilms Tumor | 2002 |
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Remission Induction; Seminoma; Survival Analysis; Survival Rate; Testicular Neoplasms; Treatment Outcome; Vincristine | 2002 |
Phase I trial of a new form of an oral administration of VP-16-213.
Topics: Administration, Oral; Adult; Aged; Capsules; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Podophyllotoxin | 1979 |
Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Growth Disorders; Hematologic Diseases; Humans; Infant; Intellectual Disability; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Nervous System Diseases; Radiation Injuries; Remission Induction; Salvage Therapy; Treatment Outcome; Vincristine | 1992 |
A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Testicular Neoplasms; Vinblastine | 1991 |
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lomustine; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Vincristine | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Stomatitis | 1991 |
A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC Lung Cancer Working Party (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1985 |
Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Topics: Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Random Allocation | 1986 |
A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation | 1986 |
Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Random Allocation | 1986 |
The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Random Allocation | 1987 |
Phase II study of etoposide for carcinoma of the prostate.
Topics: Blood Cell Count; Clinical Trials as Topic; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Male; Podophyllotoxin; Prostatic Neoplasms | 1986 |
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Topics: Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Podophyllotoxin | 1986 |
54 other study(ies) available for etoposide and Blood Diseases
| Article | Year |
|---|---|
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Croatia; Cyclophosphamide; Doxorubicin; Etoposide; Hematologic Diseases; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Rituximab; Vincristine | 2023 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
Should we replace etoposide phosphate by etoposide for allogeneic hematopoetic stem-cell transplantation in children?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Child; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Organophosphorus Compounds; Prognosis; Transplantation Conditioning; Transplantation, Homologous | 2018 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Preoperative Care; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Glioblastoma; Hematologic Diseases; Humans; Ifosfamide; Interferons; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2013 |
First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Topics: Adult; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Retroperitoneal Neoplasms; Retrospective Studies; Survival Rate; Testicular Neoplasms | 2013 |
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Etoposide; Febrile Neutropenia; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Diseases; Treatment Outcome | 2015 |
Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Korea; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sepsis; Treatment Outcome; Vincristine; Young Adult | 2009 |
Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Etoposide; Female; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Survival Rate; Thiotepa; Treatment Outcome | 2009 |
[The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Ependymoma; Etoposide; Female; Glioblastoma; Hematologic Diseases; Humans; Ifosfamide; Infant; Male; Medulloblastoma; Middle Aged; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Retrospective Studies | 2010 |
[Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Dacarbazine; Discriminant Analysis; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Male; Middle Aged; Models, Statistical; Prognosis; Risk Factors; Vinblastine | 2010 |
A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Drugs, Investigational; Etoposide; HCT116 Cells; Hematologic Diseases; Hep G2 Cells; Humans; Male; Mice; Mice, Nude; Models, Biological; Naphthalenes; Topoisomerase Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine | 2002 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Germany; Hematologic Diseases; Humans; Ifosfamide; Infant; Kidney Diseases; Kidney Neoplasms; Life Tables; Lung Neoplasms; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Prognosis; Stomatitis; Survival Analysis; Thiotepa; Transplantation, Autologous; Wilms Tumor | 2002 |
Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Disease Progression; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Time Factors; Treatment Outcome | 2003 |
Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cohort Studies; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Female; Glyoxal; Hematologic Diseases; Hodgkin Disease; Humans; Ifosfamide; Male; Prednimustine; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Vinblastine; Vincristine | 2004 |
ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasms, Second Primary; Procarbazine; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2004 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Chemotherapy combination with cyclophosphamide (CTX) adriamycin (ADM), vincristine (VCR), and VP16-213 in small cell carcinoma of the lung (SCCL).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Vincristine | 1982 |
Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cisplatin; Dogs; Drug Administration Schedule; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Time Factors; Vinblastine; Vindesine | 1984 |
A phase I trial of continuous infusion VP16-213 (etoposide).
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Podophyllotoxin | 1982 |
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Topics: Abdominal Neoplasms; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infections; Male; Neoplasm Staging; Neuroblastoma; Platelet Transfusion; Remission Induction; Retrospective Studies; Thoracic Neoplasms; Vincristine | 1994 |
[Carboplatin-VP16 combination in non small cell lung cancers in the aged patient. A study of the French group in pneumology (GFPC)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; France; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1995 |
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography, High Pressure Liquid; Drug Interactions; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Phenytoin; Therapeutic Equivalency | 1994 |
Etoposide and secondary haematological malignancies: coincidence or causality?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Chromosome Aberrations; Chromosome Disorders; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Karyotyping; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary | 1993 |
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome | 1997 |
Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chorionic Gonadotropin; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Methotrexate; Pregnancy; Remission Induction; Risk Factors; Trophoblastic Neoplasms; Uterine Neoplasms | 1998 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematologic Diseases; Humans; Infant; Kidney Diseases; Lung Diseases; Male; Middle Aged; Multiple Organ Failure; Nervous System Diseases; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2000 |
Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiation Injuries; Radiotherapy; Randomized Controlled Trials as Topic; Time Factors | 2001 |
Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Preoperative Care; Prospective Studies; Radiation Injuries; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Survival Analysis; Survival Rate; Treatment Outcome | 2001 |
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Etoposide; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2001 |
Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Topics: Adult; Ambulatory Care; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins | 1992 |
Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Hematologic Diseases; Humans; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Models, Statistical | 1992 |
Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vomiting | 1990 |
Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Vincristine | 1991 |
Carboplatin dose in combination chemotherapy for testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Drug Administration Schedule; Etoposide; Hematologic Diseases; Humans; Male; Platelet Count; Testicular Neoplasms | 1991 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: association with severe toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Stomach Neoplasms | 1991 |
Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Remission Induction; Survival Rate | 1990 |
Phase II study of daily oral etoposide in refractory germ cell tumors.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Remission Induction; Retroperitoneal Neoplasms; Survival Rate; Testicular Neoplasms | 1990 |
Modification of the 8 drugs in 1 day regimen: feasibility of substitution of other agents.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Monitoring, Physiologic; Remission Induction; Risk Factors | 1990 |
An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Prednisolone; Remission Induction | 1990 |
Small cell carcinoma of the lung: influence of age on treatment outcome.
Topics: Actuarial Analysis; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged | 1987 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Stomatitis | 1986 |
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematologic Diseases; Hematuria; Hodgkin Disease; Humans; Ifosfamide; Male; Methotrexate; Middle Aged; Mitoguazone | 1987 |
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cytarabine; Drug Evaluation; Etoposide; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kidney Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged | 1987 |
Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms | 1986 |
Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoguazone | 1986 |
Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male | 1987 |
Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Male; Prednisone; Recurrence; Vincristine | 1985 |